Holen Sie sich die Stockscreener-App
18.38
1.24%
-0.23
Handel nachbörslich:
17.56
-0.82
-4.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$18.61
Offen:
$18.66
24-Stunden-Volumen:
1.21M
Relative Volume:
0.40
Marktkapitalisierung:
$861.36M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-15.71
EPS:
-1.17
Netto-Cashflow:
$-33.33M
1W Leistung:
-5.94%
1M Leistung:
-2.55%
6M Leistung:
+196.45%
1J Leistung:
+504.61%
1-Tages-Spanne:
$17.21
$19.47
1-Wochen-Bereich:
$16.77
$19.50
52-Wochen-Spanne:
$2.87
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CAPR | 18.38 | 861.36M | 27.10M | -24.31M | -33.33M | -1.17 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
HC Wainwright Brokers Increase Earnings Estimates for CAPR - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
CAPRCapricor Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Capricor Therapeutics to Present Exosome Platform Updates - GlobeNewswire
Capricor's StealthX Platform Shows Promise in DMD Treatment, Shares New Data | CAPR Stock News - StockTitan
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Average Price Target from Analysts - Defense World
Objective long/short (CAPR) Report - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6%What's Next? - MarketBeat
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline - Yahoo Finance
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 - The Manila Times
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3%Time to Sell? - MarketBeat
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength - Yahoo Finance
Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Piper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight Recommendation - MSN
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Capricor Therapeutics initiated at Overweight by Piper Sandler - MSN
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3%Here's Why - MarketBeat
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics stock outlook driven by DMD drug potential, says Piper Sandler - Investing.com Canada
Cash raises for Inventiva, Akeso, Capricor - BioCentury
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Capricor Therapeutics Announces Closing of Underwritten - GlobeNewswire
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - StockTitan
Form 424B5 CAPRICOR THERAPEUTICS, - StreetInsider.com
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownHere's What Happened - MarketBeat
Why Capricor Therapeutics (CAPR) Shares Are Trading Lower - Benzinga
Capricor Therapeutics Stock Slides After Pricing Secondary Offering, Catches Retail’s Eye - Barchart
Capricor sets public offering at $17 per share - Investing.com
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):